1-(5-苯基戊基)哌啶 | 146403-57-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 1-(5-苯基戊基)哌啶
• 英文名称: N-(5-phenylpentyl)piperidine
• 英文别名: Piperidine, 1-(5-phenylpentyl)-；1-(5-phenylpentyl)piperidine
• CAS: 146403-57-8
• 化学式: C₁₆H₂₅N
• 分子量: 231.381
• InChiKey: MRACOXALPXCQLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-(5-苯基戊基)哌啶 在 硫酸 、 硝酸 作用下， 以 溶剂黄146 为溶剂， 反应 0.5h， 以37%的产率得到1-[5-(4-Nitro-phenyl)-pentyl]-piperidine
  参考文献：
  名称：

  Is a Nitrogen Atom an Important Pharmacophoric Element in Sigma Ligand Binding?

  摘要：

  A lingering question in sigma receptor ligand development is whether a nitrogen atom serves as an important pharmacophoric clement in binding affinity. To address this question, we have synthesized several phenylalkylpiperidines and phenylalkylpiperazines and demonstrated that removal of the N atom from a typical phenylalkylpiperidine led to little or no binding to sigma receptors. Tn addition, where two N atoms occur in a compound, such as with phenylalkylpiperazines, the N atom on the longer alkyl chain appears to be more important. Thus, based on this study, the N atom is an important pharmacophoric element in the binding of phenylalkyllpiperidines and phenylalkylpiperazines to sigma receptors. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00148-6
• 作为产物：
  描述：

  哌啶 、 (5-溴正戊基)苯 在 potassium carbonate 、 potassium iodide 作用下， 以 乙二醇二甲醚 为溶剂， 反应 12.0h， 以74%的产率得到1-(5-苯基戊基)哌啶
  参考文献：
  名称：

  Is a Nitrogen Atom an Important Pharmacophoric Element in Sigma Ligand Binding?

  摘要：

  A lingering question in sigma receptor ligand development is whether a nitrogen atom serves as an important pharmacophoric clement in binding affinity. To address this question, we have synthesized several phenylalkylpiperidines and phenylalkylpiperazines and demonstrated that removal of the N atom from a typical phenylalkylpiperidine led to little or no binding to sigma receptors. Tn addition, where two N atoms occur in a compound, such as with phenylalkylpiperazines, the N atom on the longer alkyl chain appears to be more important. Thus, based on this study, the N atom is an important pharmacophoric element in the binding of phenylalkyllpiperidines and phenylalkylpiperazines to sigma receptors. (C) 2000 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(00)00148-6

文献信息

• Piperidino-Hydrocarbon compounds as novel non-Imidazole histamine H3-Receptor antagonists
  作者：Galina Meier、Xavier Ligneau、Heinz H Pertz、C.Robin Ganellin、Jean-Charles Schwartz、Walter Schunack、Holger Stark

  DOI：10.1016/s0968-0896(02)00115-3

  日期：2002.8

  In search for novel non-imidazole histamine H(3)-receptor antagonists, piperidino-hydrocarbon compounds were synthesized using the known non-imidazole histamine H(3)-receptor antagonist FUB 637 (3-phenylpropyl 3-piperidinopropyl ether) as lead structure. Piperidino-alkyl derivatives containing highly flexible side chains (2, 4-7) were prepared via N-alkylation. Compounds containing unsaturated alkyl

  为了寻找新型的非咪唑组胺H（3）-受体拮抗剂，使用已知的非咪唑组胺H（3）-受体拮抗剂FUB 637（3-苯基丙基3-哌啶基丙基醚）合成了哌啶子基烃化合物。 。通过N-烷基化制备含有高度柔性侧链（2、4-7）的哌啶子基-烷基衍生物。合成了含不饱和烷基的化合物，以研究刚性化侧链的影响（8-16）。通过乙炔化锂-乙二胺络合物的烷基化反应制备末端炔，在正丁基锂-N，N，N'，N'-N'-四亚甲基-乙二胺络合物的存在下通过适当乙炔的烷基化反应合成二取代炔烃。在豚鼠回肠的体外功能测定中研究了这些新化合物，其中N-（7-苯基庚-3-炔基）哌啶（14）被证明在此类药物中具有良好的效力（pA（2）= 7.21）。在体内试验中，还针对化合物的口服有效性和分布特性，对它们影响小鼠中枢H（3）-组胺能神经元活性的能力进行了筛选。在此筛选中，N-戊-4-炔基哌啶（9）和N-己-5-炔基哌啶（10）被证明是高效的且
• 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents
  申请人：OTSUKA PHARMACEUTICAL CO., LTD.

  公开号：EP0287951A2

  公开（公告）日：1988-10-26

  Novel 4-oxoquinoline-3-carboxylic acid compounds of the formula: wherein R¹ is cyclopropyl which may have 1 to 3 substituents of alkyl and halogen; phenyl which may be substituted by 1 to 3 substituents of alkoxy, halogen and OH; alkyl which may be substituted by halogen, alkanoyloxy or OH; alkenyl; or thienyl, R² is 5- to 9-membered saturated or unsaturated heterocyclic ring which may be sustituted, R³ is H, alkyl or halogen, R⁴ is alkyl or halogen, R is H or alkyl, R¹ and R³ may be taken together to form wherein R³¹ is H or alkyl, and X is halogen, provided that R³ and R⁴ are not simultaneously halogen, and that when R³ is H, R⁴ is alkyl, and salts thereof, said compounds having excellent anti­microbial activity and hence being useful as an antimicro­bial agent, and a pharmaceutical composition containing said compound as an active ingredient.

  式中的新型 4-氧代喹啉-3-羧酸化合物： 其中 R¹ 是环丙基，可具有 1 至 3 个烷基和卤素取代基；苯基，可被 1 至 3 个烷氧基、卤素和 OH 取代；烷基，可被卤素、烷氧基或 OH 取代；烯基；或噻吩基，R² 是 5 至 9 元饱和或不饱和杂环，可被取代，R³ 是 H、烷基或卤素，R⁴ 是烷基或卤素，R 是 H 或烷基，R¹ 和 R³ 可结合在一起形成 其中 R³¹ 是 H 或烷基，X 是卤素，条件是 R³ 和 R⁴ 不同时是卤素，当 R³ 是 H 时，R⁴ 是烷基，以及它们的盐，所述化合物具有优异的抗菌活性，因此可用作抗菌剂，以及含有所述化合物作为活性成分的药物组合物。
• Urea derivatives and their use as acat inhibitors
  申请人：NISSHIN FLOUR MILLING CO., LTD.

  公开号：EP0665216A1

  公开（公告）日：1995-08-02

  A compound of formula (I) or a pharmaceutically acceptable salt thereof (in which R₁ and R₂ each represent hydrogen, halogen or (C₁-C₆)alkoxy; R₃ and R₄ each represent hydrogen, (C₁-C₈)alkyl, cyclo(C₃-C₈)alkyl, aryl(C₁-C₆)alkyl in which the aryl moiety is optionally substituted by one or two halogen, (C₁-C₆)alkyl and/or (C₁-C₆)alkoxy, a diaryl(C₁-C₆)alkyl group, pyridyl(C₁-C₆)alkyl, diazabicyclo(C₇-C₁₀)alkyl optionally substituted by (C₁-C₆)alkyl, adamantyl or piperidyl group optionally substituted by aryl(C₁-C₆)alkyl, or R₃ and R₄, together with the nitrogen atom to which they are attached, form a 5 or 6 membered ring monocyclic, heterocyclic group optionally substituted by (C₁-C₆)alkyl; R₅ and R₇ each represent hydrogen or (C₁-C₆)alkyl; R₆ represents -OR₈ or -N(R₈)₂ wherein R₈ represents hydrogen or (C₁-C₆)alkyl, or -C(O)NHR₃ wherein R₃ is as defined above; R₆ and R₇ together may form -O-CH₂-O- which may be fused with a phenyl ring; X represents nitrogen or methine; A represents wherein R₉ represents hydrogen, (C₁-C₆)alkyl, (C₁-C₆)alkylcarbonyl, geranyl or -C(O)NHR₃, and m and n independently represent 0, 1 or 2) possess both an ACAT inhibitory activity and an antioxidative activity. Those derivatives are useful in the prophylaxis and treatment of hypercholesterolemia and atherosclerosis.

  式 (I) 的化合物或其药学上可接受的盐 (其中 R₁ 和 R₂ 各自代表氢、卤素或 (C₁-C₆)烷氧基；R₃ 和 R₄ 各自代表氢、(C₁-C₈)烷基、环(C₃-C₈)烷基、芳基(C₁-C₆)烷基，其中芳基可选择被一个或两个卤素取代、(C₁-C₆)烷基和/或 (C₁-C₆)烷氧基、二芳基(C₁-C₆)烷基、吡啶基(C₁-C₆)烷基、任选被(C₁-C₆)烷基取代的重氮双环(C₇-C₁₀)烷基、任选被芳基(C₁-C₆)烷基取代的金刚烷基或哌啶基，或 R₃ 和 R₄、和 R₄ 与它们所连接的氮原子一起形成可选被 (C₁-C₆) 烷基取代的 5 或 6 位环单环杂环基团；R₅ 和 R₇ 各自代表氢或 (C₁-C₆)烷基； R₆ 代表 -OR₈ 或 -N(R₈)₂ 其中 R₈ 代表氢或 (C₁-C₆)烷基，或 -C(O)NHR₃ 其中 R₃ 如上定义；R₆ 和 R₇ 可共同形成 -O-CH₂-O-，后者可与苯基环融合； X 代表氮或甲烷； A 代表 其中 R𠢙 代表氢、(C₁-C₆)烷基、(C₁-C₆)烷羰基、香叶基或 -C(O)NHR₃，m 和 n 独立地代表 0、1 或 2）同时具有 ACAT 抑制活性和抗氧化活性。这些衍生物可用于预防和治疗高胆固醇血症和动脉粥样硬化。
• SIGMA RECEPTOR LIGANDS AND THE USE THEREOF
  申请人：VIRGINIA COMMONWEALTH UNIVERSITY

  公开号：EP0591426A1

  公开（公告）日：1994-04-13
• US5576335A
  申请人：——

  公开号：US5576335A

  公开（公告）日：1996-11-19